Cargando…

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma

We herein report the case of a 52-year-old man with stage IV lung adenocarcinoma. The patient was negative for epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4 (EML4) /anaplastic lymphoma kinase (ALK) rearrangement. He was treated with nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakahara, Yoshiro, Fukui, Tomoya, Shirasawa, Masayuki, Harada, Shinya, Kusuhara, Seiichiro, Takakura, Akira, Yokoba, Masanori, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Masuda, Noriyuki, Inukai, Madoka, Sekiguchi, Tomoko, Naoki, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262697/
https://www.ncbi.nlm.nih.gov/pubmed/29877291
http://dx.doi.org/10.2169/internalmedicine.9884-17
_version_ 1783375162009190400
author Nakahara, Yoshiro
Fukui, Tomoya
Shirasawa, Masayuki
Harada, Shinya
Kusuhara, Seiichiro
Takakura, Akira
Yokoba, Masanori
Mitsufuji, Hisashi
Kubota, Masaru
Katagiri, Masato
Sasaki, Jiichiro
Masuda, Noriyuki
Inukai, Madoka
Sekiguchi, Tomoko
Naoki, Katsuhiko
author_facet Nakahara, Yoshiro
Fukui, Tomoya
Shirasawa, Masayuki
Harada, Shinya
Kusuhara, Seiichiro
Takakura, Akira
Yokoba, Masanori
Mitsufuji, Hisashi
Kubota, Masaru
Katagiri, Masato
Sasaki, Jiichiro
Masuda, Noriyuki
Inukai, Madoka
Sekiguchi, Tomoko
Naoki, Katsuhiko
author_sort Nakahara, Yoshiro
collection PubMed
description We herein report the case of a 52-year-old man with stage IV lung adenocarcinoma. The patient was negative for epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4 (EML4) /anaplastic lymphoma kinase (ALK) rearrangement. He was treated with nivolumab as a third-line chemotherapy. After four cycles of nivolumab treatment, a partial response was observed in the brain and at the primary tumor site. Nivolumab treatment has been continued for 11 months without progression. Immunohistochemistry revealed that the programmed death-ligand 1 (PD-L1) expression was 0% (according to the tumor proportion score). Our case indicates that the efficacy of programmed cell death 1 inhibitors is not solely predicted by the PD-L1 status, and that immune checkpoint inhibitors might be effective for the treatment of central nervous system metastasis.
format Online
Article
Text
id pubmed-6262697
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-62626972018-11-30 Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma Nakahara, Yoshiro Fukui, Tomoya Shirasawa, Masayuki Harada, Shinya Kusuhara, Seiichiro Takakura, Akira Yokoba, Masanori Mitsufuji, Hisashi Kubota, Masaru Katagiri, Masato Sasaki, Jiichiro Masuda, Noriyuki Inukai, Madoka Sekiguchi, Tomoko Naoki, Katsuhiko Intern Med Case Report We herein report the case of a 52-year-old man with stage IV lung adenocarcinoma. The patient was negative for epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4 (EML4) /anaplastic lymphoma kinase (ALK) rearrangement. He was treated with nivolumab as a third-line chemotherapy. After four cycles of nivolumab treatment, a partial response was observed in the brain and at the primary tumor site. Nivolumab treatment has been continued for 11 months without progression. Immunohistochemistry revealed that the programmed death-ligand 1 (PD-L1) expression was 0% (according to the tumor proportion score). Our case indicates that the efficacy of programmed cell death 1 inhibitors is not solely predicted by the PD-L1 status, and that immune checkpoint inhibitors might be effective for the treatment of central nervous system metastasis. The Japanese Society of Internal Medicine 2018-06-06 2018-11-01 /pmc/articles/PMC6262697/ /pubmed/29877291 http://dx.doi.org/10.2169/internalmedicine.9884-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nakahara, Yoshiro
Fukui, Tomoya
Shirasawa, Masayuki
Harada, Shinya
Kusuhara, Seiichiro
Takakura, Akira
Yokoba, Masanori
Mitsufuji, Hisashi
Kubota, Masaru
Katagiri, Masato
Sasaki, Jiichiro
Masuda, Noriyuki
Inukai, Madoka
Sekiguchi, Tomoko
Naoki, Katsuhiko
Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
title Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
title_full Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
title_fullStr Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
title_full_unstemmed Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
title_short Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
title_sort intracranial response to nivolumab in a patient with pd-l1-negative lung adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262697/
https://www.ncbi.nlm.nih.gov/pubmed/29877291
http://dx.doi.org/10.2169/internalmedicine.9884-17
work_keys_str_mv AT nakaharayoshiro intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT fukuitomoya intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT shirasawamasayuki intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT haradashinya intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT kusuharaseiichiro intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT takakuraakira intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT yokobamasanori intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT mitsufujihisashi intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT kubotamasaru intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT katagirimasato intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT sasakijiichiro intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT masudanoriyuki intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT inukaimadoka intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT sekiguchitomoko intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma
AT naokikatsuhiko intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma